Alembic Pharmaceuticals today announced that it has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Macitentan tablets, 10 mg.

The tentatively approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Opsumit tablets, 10 mg, of Actelion Pharmaceuticals US, Inc, a company statement notified.

Click for more articles on USFDA

Macitentan tablets are an Endothelin Receptor Antagonist (ERA) indicated for the treatment of Pulmonary Arterial Hypertension (PAH, WHO Group I) to delay disease progression.

Disease progression included death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased six-minute walk distance, worsened PAH symptoms and need for additional PAH treatment).

Macitentan tablets also reduced hospitalisation for PAH.

It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses, it said.

Macitentan tablets, 10 mg have an estimated market size of $797 million for twelve months ending Decemeber 2021, according to IQVIA, the statement concluded.

Other Drugs approval by USFDA

USFDA gives final nod to Zydus for Colestipol Hydrochloride tablets

USFDA gives nod to Strides Pharma for Colchicine tablets

USFDA gives nod to Alembic Pharmaceuticals for anti fungal drug

USFDA gives nod to Aleor for Nystatin and Triamcinolone Acetonide Ointment

USFDA approves expanded use of cancer drug Opdivo

USFDA gives nod to Lupin for generic Jublia topical solution

Govt releases draft National Medical Device Policy 2022

Deadline extended for proposals under PLI scheme for Bulk Drugs

USFDA gives final nod to Zydus for Colestipol Hydrochloride tablets

Orders to close these 5 Pharmaceutical units

USFDA inspections back in full swing for Pharma Companies

Drug recall: Macleods recalls products for these manufacturing issues

NITI Aayog to expand ‘Medicines from the Sky’ project

Make Pharma Companies liable for bribing doctors: PIL

USFDA issues 3 observations on Zydus manufacturing unit

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/03/15/usfda-gives-tentative-nod-to-alembic-for-macitentan-tablets-10-mg/